Armouch Mohamad C, Atef Ahmed M, Abdel Hameed Osama, Alshaikh Nada A, Elbeleidy Ahmed S, Ali Benkheder, El Najjar Lubna, Tawfik Eslam
Otolaryngology, Mediclinic Al Noor Hospital, Abu Dhabi, ARE.
Otolaryngology, Faculty of Medicine, Cairo University, Cairo, EGY.
Cureus. 2025 Apr 23;17(4):e82836. doi: 10.7759/cureus.82836. eCollection 2025 Apr.
Allergic rhinitis (AR) is a prevalent atopic condition that is frequently misdiagnosed, mistreated, or overlooked, despite its high prevalence and significant economic burden. Pharmacotherapy effectively controls symptoms in the majority of cases; however, the current local guidelines and recommendations are ambiguous regarding the initiation and cessation of combined antihistamines and intranasal corticosteroids treatment. Additionally, guidelines do not specify the duration of AR therapy or identify cases eligible for combination therapy. In contrast, the current era emphasizes personalized medicine, which considers genetic variants that may clinically alter the tolerance and intended outcome of specific drugs. Moreover, there has been a noticeable surge in the number of individuals affected by AR in the Arab region. A systematic treatment algorithm tailored to the Arab region's population is urgently needed. This consensus outlines the recommendations of experts from three scientific meetings that gathered specialists in otolaryngology, pediatrics, and immuno-allergology from Egypt, Tunisia, the Kingdom of Saudi Arabia, and the United Arab Emirates. The expert panel opinion encompassed pre-meeting surveys followed by discussions about diversified topics related to AR management in the Arab region, including AR diagnosis and disease characteristics, patient profiling, and conventional and advanced treatment options. The experts developed a streamlined algorithm to enhance decision-making for AR treatment in Arab countries, based on discussions and a comprehensive literature review. To our knowledge, this manuscript presents the first region-specific, consensus-based management algorithm tailored to the Arab region, addressing unique local considerations.
过敏性鼻炎（AR）是一种常见的特应性疾病，尽管其患病率高且经济负担重，但经常被误诊、误治或忽视。药物治疗在大多数情况下能有效控制症状；然而，目前当地的指南和建议在联合使用抗组胺药和鼻用糖皮质激素治疗的起始和停止方面并不明确。此外，指南未明确AR治疗的持续时间，也未确定适合联合治疗的病例。相比之下，当前时代强调个性化医疗，即考虑可能在临床上改变特定药物耐受性和预期疗效的基因变异。此外，阿拉伯地区受AR影响的人数显著增加。迫切需要一种针对阿拉伯地区人群的系统治疗算法。本共识概述了来自三次科学会议的专家建议，这些会议汇聚了来自埃及、突尼斯、沙特阿拉伯王国和阿拉伯联合酋长国的耳鼻喉科、儿科和免疫过敏学专家。专家小组的意见包括会前调查，随后围绕与阿拉伯地区AR管理相关的各种主题进行讨论，包括AR诊断和疾病特征、患者概况以及传统和先进的治疗选择。基于讨论和全面的文献综述，专家们制定了一种简化算法，以加强阿拉伯国家AR治疗的决策制定。据我们所知，本手稿提出了首个针对阿拉伯地区的、基于共识的特定区域管理算法，解决了当地独特的考量因素。
